FDA re­jects Co­herus' re­worked Neu­las­ta biosim­i­lar due to third-par­ty in­spec­tions

Last year
FDA+

Pfiz­er restarts pro­duc­tion at tor­na­do-hit plant, ex­pects sup­ply is­sues to per­sist in­to 2024

Last year
Manufacturing

Klick Health rolls out AI for phar­ma with first in­dus­try Chat­G­PT add-on tool

Last year
Marketing

No­var­tis spot­lights pso­ri­at­ic arthri­tis and Cosen­tyx with award-win­ning chef and restau­rant own­er

Last year
Marketing

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

Last year
Startups
R&D

An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Last year
News Briefing

Scynex­is pulls vagi­nal in­fec­tion tablet from shelves, paus­es on­go­ing tri­als on the heels of con­t­a­m­i­na­tion risk ...

Last year
Manufacturing

Bridge­Bio inks $250M PIPE two months af­ter PhI­II heart pill win, hints at more fi­nanc­ing

Last year
Financing

No­var­tis ra­di­oli­gand tri­umphs in a first-line PhI­II tri­al re­cruit­ing pa­tients with rare neu­roen­docrine tu­mors

Last year
R&D

No­vo signs up for near­ly a dozen car­diometa­bol­ic pro­grams out of Va­lo Health

Last year
Deals

FDA picks apart Brain­Stor­m's po­ten­tial ALS treat­ment ahead of Wednes­day ad­comm

Last year
Cell/Gene Tx
FDA+

Lab­corp backs Adela’s $48M Se­ries A1 to ad­vance methy­la­tion-based head and neck can­cer test

Last year
Financing

Im­mu­ni­ty­Bio lays off 50 em­ploy­ees in Flori­da and Cal­i­for­nia af­ter blad­der can­cer BLA re­jec­tion

Last year
People

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Last year
Deals
R&D

The 2023 End­points 11; Re­gen­eron’s gene edit­ing am­bi­tions; GSK’s re­search re­vamp; Rip­ple ef­fect of Dana-Far­ber, ...

Last year
Weekly

CDC ad­vi­sors rec­om­mend Pfiz­er's ma­ter­nal RSV vac­cine in 11-1 vote

Last year
Pharma
FDA+

Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

Last year
Pharma
Marketing

Boehringer In­gel­heim, Eli Lil­ly clinch new FDA ap­proval for block­buster Jar­diance to treat chron­ic kid­ney dis­ease

Last year
Pharma
FDA+

Sen­a­tors call on FDA to not risk bi­as­ing study find­ings in fa­vor of opi­oid use

Last year
Pharma

Mor­phic’s stock falls af­ter new da­ta sug­gest low­er-than-ex­pect­ed ef­fi­ca­cy for its ul­cer­a­tive col­i­tis pill 

Last year
R&D

Dex­com re­cruits new class of col­lege ath­letes with type 1 di­a­betes for spon­sor­ship deals

Last year
Pharma
Marketing

FDA ad­vi­sors unan­i­mous­ly re­ject Intar­ci­a's em­bat­tled type 2 di­a­betes treat­ment

Last year
Pharma
FDA+

Dana-Far­ber, Brigham breakup could lead to a rip­ple ef­fect for CGT clin­i­cal tri­als for can­cer

Last year
Cell/Gene Tx
In Focus

LB Phar­ma­ceu­ti­cals rais­ing $75M for schiz­o­phre­nia drug as Karuna looks to change the field

Last year
Financing
Startups
First page Previous page 275276277278279280281 Next page Last page
A service from the Financial Times